Clear Cell Renal Cell Carcinoma Metastasis to the Thyroid: A Narrative Review of the Literature

Menelaos G Samaras1, Abraham Pouliakis1, Konstantinos Skaretzos1

  • 1Second Department of Pathology, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, 15772 Athens, Greece.

Cancers
|January 10, 2026
PubMed

Insights

Clear cell renal cell carcinoma can metastasize to the thyroid gland, often presenting as a solitary nodule. Early diagnosis and treatment are crucial for managing this rare but significant complication.

Area of Science:

  • Oncology
  • Pathology
  • Radiology

Background:

  • Clear cell renal cell carcinoma (ccRCC) is the predominant histological subtype of renal cancer.
  • ccRCC is characterized by a protracted clinical course with a propensity for diverse metastatic sites.
  • Thyroid gland metastasis from ccRCC is an uncommon but clinically relevant occurrence.

Purpose of the Study:

  • To review and synthesize existing literature on thyroid metastases from ccRCC.
  • To analyze clinical, pathological, and imaging features of these metastases.
  • To evaluate therapeutic strategies and survival outcomes in patients with ccRCC thyroid metastases.

Main Methods:

  • Systematic literature search of PubMed, Scopus, and Web of Science databases.
  • Inclusion of case reports and case series published since 2011.
  • Exclusion of studies with insufficient data or non-English language publications.

Main Results:

  • Analysis of 77 reports involving 189 patients with ccRCC thyroid metastases.
  • Common imaging findings include solitary nodules (median size 3.5 cm) with ultrasonographic features like heterogeneity and hypoechogenicity.
  • Histological and immunohistochemical confirmation is essential due to non-specific imaging characteristics.

Conclusions:

  • Thyroid metastases from ccRCC necessitate histological confirmation due to variable imaging features.
  • ccRCC commonly metastasizes to the urogenital system, lungs, and pancreas.
  • Restricted mean survival from primary diagnosis was 274.6 months, and from thyroid metastasis treatment was 93.9 months, with no statistically significant impact of patient characteristics on survival.